The 114% CyPath Lung revenue growth and 146% unit sales increase confirm accelerating commercial adoption, but the $3.1M cash balance implies less than one quarter of runway at current burn rates. Watch for a near-term capital raise (equity or debt) to fund operations through 2026. The DoD-funded longitudinal trial is a positive catalyst for potential VA/military adoption, but results are months away.
Price Chart
Executive Summary
bioAffinity Technologies reported Q1 2026 revenue of $1.4M, down 27% YoY from $1.9M due to the discontinuation of unprofitable pathology services, while CyPath Lung testing revenue grew 114% to $361K. Net loss widened to $3.6M from $2.7M, and cash burn reduced reserves from $6.4M to $3.1M. The core diagnostic franchise is growing rapidly, but the company remains pre-profitability with a cash runway of under one quarter at current burn rates.
Key Financial Metrics
Key Facts
- Total consolidated revenue decreased ~27% YoY to $1.4M from $1.9M
- CyPath Lung testing revenue increased ~114% to $361K from $169K
- CyPath Lung unit sales rose 146% YoY
- Net loss widened to $3.6M ($0.81/share) from $2.7M ($4.80/share)
- Cash and equivalents fell to $3.1M from $6.4M at year-end 2025
- Operating expenses rose to $5.0M from $4.5M, driven by SG&A expansion
- Physician offices/clinics ordering CyPath Lung increased 69% YoY
- Longitudinal clinical trial launched with DoD funding, up to 20 sites
Financial Impact
Revenue decline of ~$0.5M YoY; cash burn of ~$3.5M in Q1; CyPath Lung revenue growth of ~$192K
Risk Factors
- Cash runway of less than one quarter at current burn rate — likely needs financing soon
- Total revenue continues to decline as legacy pathology services are wound down
- Net loss widening despite CyPath growth; path to profitability unclear
- Micro-cap with $1M market cap — extreme volatility and liquidity risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-021861 |
| Document: form8-k.htm | 0001493152-26-021861 |
| Document: 0001493152-26-021861-index-headers.html | 0001493152-26-021861 |
| Document: 0001493152-26-021861-index.html | 0001493152-26-021861 |
| Document: 0001493152-26-021861.txt | 0001493152-26-021861 |
| 8-K Data (Synthetic) | 0001493152-26-021861 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 2, 2026 20w ago | 8-K | $0.2950 $0.1300 | ▼ −55.93% | ▼ −54.37% | — |
May 27, 2026 21w ago | 8-K | $0.2950 $0.2950 | · 0.00% | ▲ +1.90% | — |
May 13, 2026 23w ago | EFFECT | $0.2950 $0.2950 | · 0.00% | ▲ +0.61% | — |
May 12, 2026 23w ago | 8-K | $0.2950 $0.2950 | · 0.00% | ▲ +1.73% | — |
May 8, 2026 24w ago | 8-K | $0.2950 $0.2950 | · 0.00% | ▼ −0.02% | — |
Apr 14, 2026 27w ago | 8-K | $0.2950 $0.2950 | · 0.00% | ▼ −6.30% | — |
Apr 7, 2026 28w ago | 8-K | $0.2950 $0.2950 | · 0.00% | ▼ −9.78% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers